Risk of infection and wound dehiscence after use of prophylactic antibiotics in episiotomy or second degree tear (REPAIR study): single centre, double blind, placebo controlled randomised trial.

10 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 6 tests: 6 consistent, 0 inconsistent, 6 via agent-written checks.

2 copyedit issues flagged: mostly consistency, other.

Checked 24 references: 17 verified — 7 not checked.

2 data/code links checked; 2 live.

Ready after minor edits. The two warn-dimension gaps (drug manufacturer, code repository) and the copyedit issues (spelling consistency, code link) should be addressed before submission; none of these affect the scientific validity of the trial.

1. 1.
   HIGHrigor

   Add the manufacturer/source (including city/country) for amoxicillin/clavulanic acid and placebo tablets in the Methods, Intervention section.

   Reagent identification standards require a traceable source for reproducibility; reviewers and editors will flag this absence.
2. 2.
   HIGHdata code

   Deposit the analysis code in a version-controlled public repository (e.g., GitHub, Zenodo) with a persistent DOI, and update the Data Availability Statement to reference the repository link.

   Code in supplemental files is less discoverable and reproducible; a public repository with a persistent identifier is the standard for code sharing.
3. 3.
   MEDIUMreporting

   Explicitly state how each limitation of prior work (high loss to follow-up, no placebo control, no clinical consultation) is addressed by the current study design in the Introduction.

   Strengthens the scientific premise by showing a systematic approach to mitigating known weaknesses, as recommended by reporting guidelines.
4. 4.
   MEDIUMreporting

   Include a statement in Methods, Randomisation on how the randomization code was generated (specific software or algorithm) and whether data analysts were blinded during analysis.

   Improves reproducibility and transparency of the randomization and analysis phases, as suggested by one reviewer.
5. 5.
   MEDIUMreporting

   Provide a direct hyperlink to the supplemental files containing the analysis code in the Data Availability Statement.

   The copyedit pass noted that a direct URL would improve accessibility; currently only a vague statement is given.
6. 6.
   MEDIUMreporting

   Report the exact time (hours post-delivery) of the first antibiotic dose relative to delivery in the Methods, Intervention section.

   Allows secondary analyses of timing effects and improves reproducibility of the intervention protocol.
7. 7.
   MEDIUMreporting

   Add a formal power calculation or justification for the secondary outcome (clinically relevant wound complications) in the Methods, Sample size or Discussion.

   Helps readers interpret the significance of the secondary finding and assess whether it was adequately powered.
8. 8.
   LOWreporting

   Report the number of women screened, eligible, and enrolled (if not already in the CONSORT flow diagram) to fully document the selection process.

   Improves assessment of selection bias and external validity, as noted by one reviewer.
9. 9.
   LOWreporting

   Describe the method for handling missing data in the primary ITT analysis (e.g., multiple imputation, complete-case) in the Methods, Statistical analysis section.

   Currently only ITT is stated; specifying how missing outcomes were handled strengthens the robustness of the analysis.
10. 10.
    LOWcopyedit

    Unify spelling of 'randomization' (American) and 'randomisation' (British) throughout the manuscript, choosing one style consistently.

    Minor consistency issue flagged by the copyedit pass; a clean manuscript avoids such distractions.
11. 11.
    LOWreporting

    Explicitly note that race/ethnicity data were not collected (already acknowledged as a limitation) and consider stating this in the Methods, Participants section.

    Addresses the 'reported_but_inadequate' rating for demographics by making the absence transparent.